Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: webmd  health  healthcare  medical  treatment  migraine  headache  robin  roberts  multivu  7579759  bloodcenter  health  healthcare  thrombocytopenia  blood  treatment  multivu  8126851  fda  brain  cancer  health  healthcare  treatment  medicine  glioma  multivu  7944251  cancer  health  kids  st  jude  home  treatment  research  showcase  tour  house  multivu  8011654  coppertone  sunburn  skin  health  sun  damage  sun  tanning  sunscreen  commercial  family  multivu  8113551  california  almonds  food  almonds  energy  health  nuts  anna  camp  commercial  multivu  8118051  johnson  johnson  medical  devices  health  healthcare  jjmd  cost  treatment  multivu  8119051  webmd  health  healthcare  dr  juan  home  remedies  treatment  medical  multivu  7579758  blink  health  health  healthcare  type  2  diabetes  treatment  medication  money  multivu  8117451  st  jude  cancer  health  healthcare  kids  childhood  treatment  research  multivu  7924756    care  colgate  karent  sierra  teeth  smile  hispanics  tips  myths  health  multivu  8103451  health  medicine  pharmaceuticals  gw  manufacturing  drugs  epileptic  treatment  pills  multivu  8109951 
Search // health
Results 1-12 of 998 for ' health ' (0 seconds)
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma. The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor. To view the multimedia release go to: https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Categories // Miscellaneous 
Added: 4 days ago by MultiVuVideos
Runtime: 4m28s | Views: 3 | Comments: 0
Not yet rated
 

 

 

Summit Homes, a Berkshire Hathaway subsidiary through Clayton Properties Group, presented St. Jude Children’s Research Hospital representatives a check for $718,000 following the sale of the builder’s 2017 St. Jude Dream Home Showplace. Summit Homes, the largest new home builder in Kansas City, built the 2017 St. Jude Dream Home Showplace as an extension of the St. Jude Dream Home® Giveaway Program, to support children battling cancer and other catastrophic diseases. The builder pledged 100% of proceeds from the sale of the home to as a donation for the research hospital. To view the multimedia release go to: https://www.multivu.com/players/English/8011654-clayton-summit-homes-st-jude-dream-home-2017/
Categories // Miscellaneous 
Added: 7 days ago by MultiVuVideos
Runtime: 3m50s | Views: 3 | Comments: 0
Not yet rated
 

 

 

Bayer, the maker of Coppertone®, is revolutionizing the sunscreen experience this season with new Coppertone® Whipped, a transformative sunscreen unlike anything you’ve ever felt before. Not only is Coppertone introducing the first ever whipped sunscreen, it is rolling out a series of engaging activations throughout the summer to launch it, and partnering with everyone from beauty influencers to the Skin Cancer Foundation. The Whipped line, available in both CLEARLYSheer® and WaterBABIES® Pure & Simple formulas, transforms the sunscreen application process from an ordinary task to an experience people can look forward to before they head out into the sunshine. While many other sunscreen lotions can feel heavy or sticky, Whipped has a rich and creamy texture, yet it absorbs quickly and feels light on skin. Plus it won't clog pores and leaves skin feeling soft and smooth while helping to protect it from the sun's harmful UV rays. To view the multimedia release go to: https://www.multivu.com/players/English/8113551-coppertone-sunscreen-clearlysheer-whipped/
Categories // Miscellaneous 
Added: 11 days ago by MultiVuVideos
Runtime: 1m9s | Views: 4 | Comments: 0
Not yet rated
 

 

 

When the mid-afternoon rolls around, many of us wouldn’t mind curling up in bed and taking a nap. In fact, a recent study conducted by GfK’s KnowledgePanel® found that one-third of Americans say they feel drowsy, less productive and worn out several times a week, at an average of 2:58 pm. This afternoon crash can be improved with the help of a healthy snack like almonds. Together, California Almonds and actress Anna Camp have partnered to ensure Americans can “Carpe PM” – or “seize the afternoon” -- and crunch their crash. To view the multimedia release go to: https://www.multivu.com/players/English/8118051-california-almonds-anna-camp-carpe-pm/
Categories // Miscellaneous 
Added: 12 days ago by MultiVuVideos
Runtime: 2m9s | Views: 5 | Comments: 0
Not yet rated
 

 

 

Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) – CareAdvantage. This is a data-driven, holistic approach in which JJMD partners with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities. The healthcare marketplace is changing, with intensifying pressure to meet the ‘triple aim’ of improving outcomes, increasing patient satisfaction and reducing costs. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients. To view the multimedia release go to: https://www.multivu.com/players/uk/8119051-johnson-medical-devices-careadvantage/
Categories // Miscellaneous 
Added: 14 days ago by MultiVuVideos
Runtime: 2m14s | Views: 2 | Comments: 0
Not yet rated
 

 

 

Today, WebMD released My Abuelita Told Me, a new five-part video series developed in partnership with Dr. Juan Rivera (“Dr. Juan”), a board-certified internist and cardiologist, who is well-known for his best-selling books and regular appearances on broadcast television. My Abuelita Told Me explores the reliability of the various home remedies, beliefs and established practices that beloved abuelitas (a.k.a. grandmas) have passed down through the generations, and Dr. Juan clarifies what is or isn’t accurate using medical science. To view the multimedia release go to: https://www.multivu.com/players/English/7579758-webmd-my-abuelita-told-me-bilingual-video-series/
Categories // Miscellaneous 
Added: 17 days ago by MultiVuVideos
Runtime: 0m13s | Views: 4 | Comments: 0
Not yet rated
 

 

 

Blink Health, America’s leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes. People living with diabetes who create an account on Blink Health’s website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone. The program will also cover these three medications for existing Blink Health patients who use them. To view the multimedia release go to: https://www.multivu.com/players/English/8117451-blink-health-type-2-diabetes-medications/
Categories // Miscellaneous 
Added: 18 days ago by MultiVuVideos
Runtime: 0m15s | Views: 5 | Comments: 0
Not yet rated
 

 

 

Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital. “This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.” To view the multimedia release go to: https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
Categories // Miscellaneous 
Added: 23 days ago by MultiVuVideos
Runtime: 1m19s | Views: 4 | Comments: 0
Not yet rated
 

 

 

Colgate announces a new addition to the Colgate Total® portfolio: Colgate Total® Clean-In-Between toothpaste. Building on the superior cleaning benefits of Colgate Total that consumers have come to expect, Clean-In-Between toothpaste’s advanced micro-foaming formula reaches even deep in between teeth to reduce 83 percent more plaque germs than non-antibacterial fluoride toothpaste 12 hours after brushing for healthier gums*. Hispanics are one of the demographic populations with the poorest oral health of any racial and ethnic groups in the United States1. In spite of brushing twice a day, plaque can build up between teeth, which affects overall gum health. Colgate Total Clean-In-Between toothpaste provides 12-hour antibacterial protection for 100% of the mouth’s surfaces: teeth, tongue, cheeks and gums. To view the multimedia release go to: https://www.multivu.com/players/English/8103451-colgate-total-simplemente-saludable-initiative/
Categories // Miscellaneous 
Added: 27 days ago by MultiVuVideos
Runtime: 0m57s | Views: 4 | Comments: 0
Not yet rated
 

 

 

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. To view the multimedia release go to: https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Categories // Miscellaneous 
Added: 31 days ago by MultiVuVideos
Runtime: 3m35s | Views: 2 | Comments: 0
Not yet rated
 

 

 

We get it, filters are the perfect skin fix for all things social, but what about your real-life beauty routine? Ditch the filters and take the #peelchallenge with Exuviance Performance Peel AP25 to reveal your own radiant, glowing complexion. Experience the benefits of this high performance 25% blend of Alpha and Poly Hydroxy Acids including Glycolic Acid, Mandelic Acid, and Gluconolactone. Exuviance Performance Peel AP25, developed by the original patent holders of the Glycolic Acid peel, exfoliates dead, dull surface layers, and encourages cell renewal for fresher, healthier-looking skin. To view the multimedia release go to: https://www.multivu.com/players/English/7965751-exuviance-performance-peelchallenge-ap25/
Categories // Miscellaneous 
Added: 33 days ago by MultiVuVideos
Runtime: 0m39s | Views: 5 | Comments: 0
Not yet rated
 

 

 

Hunova, the first robotic gym for the rehabilitation and functional motor sense evaluation of lower limbs and trunk, has been officially launched in Genoa, Italy. The first 30 robots will be available from June in Europe and the USA. The technology was developed and patented at the IIT laboratories and has been launched on the market thanks to a 10 million euro investment from entrepreneur Sergio Dompè. Hunova is a programmable robotic medical device that allows professionals in the geriatrics, neurology and sport rehabilitation field to cure and predict many neurological and orthopedic conditions. There are two main competitive advantages of this technology: Hunova is able to collect a significant amount of data on biomechanics, constantly monitoring the patient’s progress. Secondly, it provides direct support to the patient through a guiding robotic system, offering a wide range of rehabilitation protocols in the form of video games. It consists of two electromechanical platforms equipped with sensors, characterized by two degrees of freedom (feet and seat level). The device integrates the force sensors to adjust the interaction with the patient and a wireless sensor, which is placed on the patient’s trunk, allowing the physiotherapist to check the movement of the torso. To view the multimedia release go to: https://www.multivu.com/players/uk/8108951-iit-movendo-launch-robot-hunova/
Categories // Miscellaneous 
Added: 33 days ago by MultiVuVideos
Runtime: 3m28s | Views: 2 | Comments: 0
Not yet rated
 

 

 

Page 1 of 84  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2017 ClipMoon.com. All rights reserved.